Epigenetics in myeloproliferative neoplasms.
DNA methylation
JAK2
NFE2
epigenetics
histone modification
myeloproliferative neoplasms
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2023
2023
Historique:
received:
16
04
2023
accepted:
27
06
2023
medline:
31
7
2023
pubmed:
31
7
2023
entrez:
31
7
2023
Statut:
epublish
Résumé
The myeloproliferative neoplasms (MPNs) are a group of acquired clonal disorders where mutations drive proliferative disease resulting in increased blood counts and in some cases end-stage myelofibrosis. Epigenetic changes are the reversible modifications to DNA- and RNA-associated proteins that impact gene activity without changing the DNA sequence. This review summarizes mechanisms of epigenetic changes and the nucleosome. The drivers and epigenetic regulators in MPNs are outlined. In MPNs, distinct patterns of epigenetic dysregulation have been seen in chronic and in advanced phases. Methylation age and histone modification are altered in MPNs and by further treatment. The alterations found in methylation age in MPNs and with treatment are discussed, and the changes in histone modification with Janus kinase (JAK) inhibition are evaluated. Currently available therapeutic areas where the epigenome can be altered are outlined. Thus, we review the current knowledge and understanding of epigenetics in MPN and consider further management options. Understanding the epigenome and its alteration in MPNs and epigenetic changes associated with the progression of disease will lead to advances in therapeutic options.
Identifiants
pubmed: 37519812
doi: 10.3389/fonc.2023.1206965
pmc: PMC10373880
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
1206965Informations de copyright
Copyright © 2023 Greenfield and McMullin.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Blood. 2011 Nov 10;118(19):5227-34
pubmed: 21921040
J Hematol Oncol. 2022 Sep 6;15(1):127
pubmed: 36068610
Signal Transduct Target Ther. 2023 Feb 17;8(1):71
pubmed: 36797244
Int J Mol Sci. 2020 Dec 14;21(24):
pubmed: 33327550
J Exp Med. 2012 Jan 16;209(1):35-50
pubmed: 22231305
J Clin Invest. 2013 Nov;123(11):4627-40
pubmed: 24216483
Cancer Res. 2004 Jan 15;64(2):689-95
pubmed: 14744786
Br J Haematol. 2013 Aug;162(4):498-508
pubmed: 23758082
Front Genet. 2018 Oct 23;9:493
pubmed: 30405699
Nat Rev Cancer. 2011 Sep 23;11(10):726-34
pubmed: 21941284
Cell. 2007 Feb 23;128(4):693-705
pubmed: 17320507
Leuk Res. 2023 Jul;130:107309
pubmed: 37210875
Lancet. 2005 Mar 19-25;365(9464):1054-61
pubmed: 15781101
Blood Cancer J. 2021 Mar 6;11(3):53
pubmed: 33677466
Blood. 2017 Oct 26;130(17):1889-1897
pubmed: 29074595
Cell. 2012 Jul 6;150(1):12-27
pubmed: 22770212
Nat Rev Mol Cell Biol. 2015 Sep;16(9):519-32
pubmed: 26296162
Leukemia. 2016 Aug;30(8):1701-7
pubmed: 27211272
Nature. 1997 Sep 25;389(6649):349-52
pubmed: 9311776
Br J Haematol. 2005 Apr;129(1):138-50
pubmed: 15801966
MedComm (2020). 2023 May 20;4(3):e292
pubmed: 37220590
Hemasphere. 2018 Jun 08;2(3):e54
pubmed: 31723778
Blood. 2016 Mar 10;127(10):1307-16
pubmed: 26817954
Cancer Cell. 2011 Feb 15;19(2):283-94
pubmed: 21316606
Cancer. 2008 Jun;112(11):2341-51
pubmed: 18398832
N Engl J Med. 2010 Dec 16;363(25):2424-33
pubmed: 21067377
Blood. 2018 May 3;131(18):2065-2073
pubmed: 29519804
Blood. 2022 May 5;139(18):2797-2815
pubmed: 35286385
Nature. 2009 Oct 8;461(7265):819-22
pubmed: 19783980
Cancer Res. 2013 Feb 1;73(3):1076-85
pubmed: 23066032
Leukemia. 2011 Jul;25(7):1217-9
pubmed: 21537334
Blood. 2010 Jul 15;116(2):254-66
pubmed: 20339092
Nat Genet. 2006 Sep;38(9):1071-6
pubmed: 16892059
N Engl J Med. 2012 Mar 1;366(9):799-807
pubmed: 22375971
N Engl J Med. 2010 Jan 28;362(4):369-70
pubmed: 20107228
BMC Cancer. 2019 Jun 17;19(1):590
pubmed: 31208359
Curr Hematol Malig Rep. 2018 Oct;13(5):369-382
pubmed: 30112706
Blood. 2017 Dec 7;130(23):2475-2483
pubmed: 29212804
Genome Biol. 2014 Feb 03;15(2):R24
pubmed: 24490752
N Engl J Med. 2015 Feb 12;372(7):601-612
pubmed: 25671252
Blood. 2008 Aug 15;112(4):1402-12
pubmed: 18515659
Adv Cancer Res. 2004;91:137-68
pubmed: 15327890
Blood. 2019 Dec 5;134(23):2107-2111
pubmed: 31578205
N Engl J Med. 2016 Sep 1;375(9):900-1
pubmed: 27579651
J Biol Chem. 2006 Jun 30;281(26):18177-83
pubmed: 16632470
Leukemia. 2010 Jul;24(7):1290-8
pubmed: 20508609
J Med Chem. 2023 Apr 13;66(7):4275-4293
pubmed: 37014989
Leukemia. 2013 Jun;27(6):1301-9
pubmed: 23486531
N Engl J Med. 2007 Feb 1;356(5):459-68
pubmed: 17267906
Cancer Cell. 2012 Aug 14;22(2):180-93
pubmed: 22897849
Oncogene. 2002 Aug 12;21(35):5483-95
pubmed: 12154409
N Engl J Med. 2013 Dec 19;369(25):2391-2405
pubmed: 24325359
J Exp Med. 2013 May 6;210(5):1003-19
pubmed: 23589569
J Exp Med. 2016 Jul 25;213(8):1459-77
pubmed: 27401345
N Engl J Med. 2018 Oct 11;379(15):1416-1430
pubmed: 30304655
Proc Natl Acad Sci U S A. 2002 Sep 3;99(18):11700-5
pubmed: 12189205
Cancers (Basel). 2020 Sep 18;12(9):
pubmed: 32962027
Methods Mol Biol. 2002;200:1-7
pubmed: 11951645
Genome Biol. 2013;14(10):R115
pubmed: 24138928
Haematologica. 2013 Sep;98(9):1414-20
pubmed: 23716560
Onco Targets Ther. 2020 Dec 01;13:12367-12382
pubmed: 33293830
N Engl J Med. 2009 May 28;360(22):2289-301
pubmed: 19474426
Leukemia. 2005 Oct;19(10):1751-9
pubmed: 16121216
Exp Hematol. 2019 Nov;79:26-34
pubmed: 31563618
Leukemia. 2009 Nov;23(11):2183-6
pubmed: 19609284
Biochim Biophys Acta. 2014 Aug;1839(8):676-85
pubmed: 24686119
Leuk Res. 2023 Jun;129:107077
pubmed: 37100025
J Clin Pathol. 2011 Nov;64(11):1010-3
pubmed: 21821860